Patent · US Active

Molecular targets for the prevention and/or treatment of fibrosis, hypertrophic scars or keloids

US9840704B2 · kind B2 · utility

0Cited by

0References

12Claims

0Family size

Assignees

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE · FR
INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) · FR
URGO RECHERCHE INNOVATION ET DEVELOPPEMENT · FR
UNIVERSITÉ PARIS DIDEROT—PARIS 7 · FR
ECOLE NORMALE SUPERIEURE · FR

Inventors

Claire Dugast-Darzacq · Antony, FR
Maïté Noizet · Versailles, FR
Xavier Darzacq · Antony, FR

Key dates

Filing date	Jul 30, 2014
Grant date	Dec 12, 2017
Priority date	—
Expiry date	Jul 30, 2034

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2320/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a therapeutic compound comprising: an agent that inhibits the activity of at least one gene selected from the group consisting of HIC1, FOXS1, CREB5, IRF7, POU2F2, STAT4, TCF4, and/or an agent that enhances the activity of at least one gene selected from the group consisting of MAF, MEOX2, SIX2.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.